Intranasal Carbetocin (LV-101) Enters Phase 3 Trial for Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) is a complex, rare genetic disorder stemming from a deletion or unmethylation on chromosome 15, leading to hypothalamic dysfunction. This manifests as severe, unremitting hunger (hyperphagia), which often results in morbid obesity, alongside cognitive impairment, behavioral problems, and endocrine abnormalities. Current management is largely supportive, focusing on strict dietary control and growth hormone therapy, but no approved pharmacological treatments directly address the debilitating hyperphagia or neurobehavioral issues. Oxytocin, a neuropeptide involved in social behavior, satiety, and reward pathways, is hypothesized to be deficient or dysregulated in PWS, making its synthetic analog, carbetocin, a promising therapeutic candidate.

This is a Phase 3 clinical study designed to evaluate the effectiveness, safety, and tolerability of intranasal carbetocin (LV-101) in patients with Prader-Willi Syndrome. The study aims to assess whether carbetocin, an oxytocin analog, can improve symptoms associated with PWS. Specific details regarding dose, frequency, duration, and primary efficacy endpoints are not provided in this abstract, but the overall goal is to establish its therapeutic potential in a pivotal trial setting.